阴道微生态与人乳头瘤病毒感染及宫颈病变的相关性

doi:10.12280/gjfckx.20230018

摘要/Abstract

摘要：

宫颈癌是全球女性生殖道肿瘤中最常见的恶性肿瘤之一，近年来发病率逐年升高。宫颈癌的致病因素相对明确，几乎所有的宫颈癌病例都与人乳头瘤病毒（human papilloma virus，HPV）感染有关。此外，多个性伴侣、初次性生活年龄小和吸烟等不良生活习惯也是宫颈病变的高危因素。近年来，随着阴道微生态研究的不断深入，研究者发现阴道微生态可以调节HPV感染，并在宫颈癌前病变和浸润性宫颈癌的发展中起着至关重要的作用，可能作为宫颈癌检测的潜在生物标志物。深入研究阴道微生态与宫颈病变及HPV感染的内在联系对于宫颈癌的预防及早期治疗具有重大意义。

关键词: 宫颈肿瘤, 宫颈上皮内瘤样病变, 乳杆菌属, 乳头状瘤病毒科, 乳头状瘤病毒疫苗, 阴道微生态

Abstract:

Cervical cancer is one of the most common malignancies of the female reproductive tract worldwide, and its incidence has been increasing year by year in recent years. The etiology of cervical cancer is relatively clear, almost all cases of cervical cancer being associated with human papilloma virus (HPV) infection. In addition, poor lifestyle habits such as multiple sexual partners, young age at first sex and smoking are high risk factors for cervical lesions. In recent years, with the continuous research on vaginal microecology, researchers have discovered that vaginal microecology can regulate HPV infection and play a crucial role in the development of cervical precancerous lesions and invasive cervical cancer, which may serve as a potential biomarker for cervical cancer detection. In-depth study of the intrinsic link between vaginal microecology, cervical lesions and HPV infection is of great significance for the prevention and early treatment of cervical cancer.

Key words: Uterine cervical neoplasms, Cervical intraepithelial neoplasia, Lactobacillus, Papillomaviridae, Papillomavirus vaccines, Vaginal microecology

丛蓉, 翟青枝. 阴道微生态与人乳头瘤病毒感染及宫颈病变的相关性[J]. 国际妇产科学杂志, 2023, 50(3): 286-289.

CONG Rong, ZHAI Qing-zhi. Correlation of Vaginal Microecology with HPV Positivity and Cervical Lesions[J]. Journal of International Obstetrics and Gynecology, 2023, 50(3): 286-289.

参考文献 39

[1]	Li M, Zhao C, Zhao Y, et al. Association and Effectiveness of PAX1 Methylation and HPV Viral Load for the Detection of Cervical High-Grade Squamous Intraepithelial Lesion[J]. Pathogens, 2022, 12(1):63. doi: 10.3390/pathogens12010063. doi: 10.3390/pathogens12010063
[2]	Xia C, Li S, Long T, et al. Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia[J]. Cancers(Basel), 2021, 13(11):2691. doi: 10.3390/cancers13112691. doi: 10.3390/cancers13112691
[3]	Qingqing B, Jie Z, Songben Q, et al. Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection[J]. Microb Pathog, 2021, 152:104617. doi: 10.1016/j.micpath.2020.104617. doi: 10.1016/j.micpath.2020.104617
[4]	Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer[J]. J Natl Cancer Inst, 2021, 113(10):1329-1335. doi: 10.1093/jnci/djab080. doi: 10.1093/jnci/djab080 pmid: 33876216
[5]	Yang D, Zhang J, Cui X, et al. Risk Factors Associated With Human Papillomavirus Infection, Cervical Cancer, and Precancerous Lesions in Large-Scale Population Screening[J]. Front Microbiol, 2022, 13:914516. doi: 10.3389/fmicb.2022.914516. doi: 10.3389/fmicb.2022.914516
[6]	Castle PE, Einstein MH, Sahasrabuddhe VV. Cervical cancer prevention and control in women living with human immunodeficiency virus[J]. CA Cancer J Clin, 2021, 71(6):505-526. doi: 10.3322/caac.21696. doi: 10.3322/caac.21696
[7]	Blagosklonny MV. Hallmarks of cancer and hallmarks of aging[J]. Aging(Albany NY), 2022, 14(9):4176-4187. doi: 10.18632/aging.204082. doi: 10.18632/aging.204082
[8]	Liu J, Luo M, Zhang Y, et al. Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition[J]. Ann Transl Med, 2020, 8(18):1161. doi: 10.21037/atm-20-5832. doi: 10.21037/atm-20-5832 pmid: 33241010
[9]	Wang W, Liu Y, Yang Y, et al. Changes in vaginal microbiome after focused ultrasound treatment of high-risk human papillomavirus infection-related low-grade cervical lesions[J]. BMC Infect Dis, 2023, 23(1):3. doi: 10.1186/s12879-022-07937-8. doi: 10.1186/s12879-022-07937-8 pmid: 36604622
[10]	Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women[J]. Proc Natl Acad Sci U S A, 2011, 108(Suppl 1):4680-4687. doi: 10.1073/pnas.1002611107. doi: 10.1073/pnas.1002611107
[11]	Chee W, Chew SY, Than L. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health[J]. Microb Cell Fact, 2020, 19(1):203. doi: 10.1186/s12934-020-01464-4. doi: 10.1186/s12934-020-01464-4 pmid: 33160356
[12]	Kaul R, Liu CM, Park DE, et al. The Penis, the Vagina and HIV Risk: Key Differences (Aside from the Obvious)[J]. Viruses, 2022, 14(6):1164. doi: 10.3390/v14061164. doi: 10.3390/v14061164
[13]	Zheng N, Guo R, Wang J, et al. Contribution of Lactobacillus iners to Vaginal Health and Diseases: A Systematic Review[J]. Front Cell Infect Microbiol, 2021, 11:792787. doi: 10.3389/fcimb.2021.792787. doi: 10.3389/fcimb.2021.792787
[14]	Joseph RJ, Ser HL, Kuai YH, et al. Finding a Balance in the Vaginal Microbiome: How Do We Treat and Prevent the Occurrence of Bacterial Vaginosis?[J]. Antibiotics(Basel), 2021, 10(6):719. doi: 10.3390/antibiotics10060719. doi: 10.3390/antibiotics10060719
[15]	Mei Z, Li D. The role of probiotics in vaginal health[J]. Front Cell Infect Microbiol, 2022, 12:963868. doi: 10.3389/fcimb.2022.963868. doi: 10.3389/fcimb.2022.963868
[16]	Borgogna JC, Shardell MD, Santori EK, et al. The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis[J]. BJOG, 2020, 127(2):182-192. doi: 10.1111/1471-0528.15981. doi: 10.1111/1471-0528.15981
[17]	Chetwin E, Manhanzva MT, Abrahams AG, et al. Antimicrobial and inflammatory properties of South African clinical Lactobacillus isolates and vaginal probiotics[J]. Sci Rep, 2019, 9(1):1917. doi: 10.1038/s41598-018-38253-4. doi: 10.1038/s41598-018-38253-4 pmid: 30760770
[18]	Li L, Ding L, Gao T, et al. Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China[J]. J Cancer, 2020, 11(2):284-291. doi: 10.7150/jca.35022. doi: 10.7150/jca.35022 pmid: 31897224
[19]	Zeng M, Li X, Jiao X, et al. Roles of vaginal flora in human papillomavirus infection, virus persistence and clearance[J]. Front Cell Infect Microbiol, 2022, 12:1036869. doi: 10.3389/fcimb.2022.1036869. doi: 10.3389/fcimb.2022.1036869
[20]	Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers[J]. Cancer Biol Med, 2020, 17(4):864-878. doi: 10.20892/j.issn.2095-3941.2020.0370. doi: 10.20892/j.issn.2095-3941.2020.0370 pmid: 33299640
[21]	Kyrgiou M, Moscicki AB. Vaginal microbiome and cervical cancer[J]. Semin Cancer Biol, 2022, 86(Pt 3):189-198. doi: 10.1016/j.semcancer.2022.03.005. doi: 10.1016/j.semcancer.2022.03.005 pmid: 35276341
[22]	Paula Almeida Cunha A, Kassandra Pereira Belfort I, Pedro Belfort Mendes F, et al. Human papillomavirus and Its Association with Other Sexually Transmitted Coinfection among Sexually Active Women from the Northeast of Brazil[J]. Interdiscip Perspect Infect Dis, 2020, 2020:8838317. doi: 10.1155/2020/8838317. doi: 10.1155/2020/8838317
[23]	Zheng JJ, Miao JR, Wu Q, et al. Correlation between HPV-negative cervical lesions and cervical microenvironment[J]. Taiwan J Obstet Gynecol, 2020, 59(6):855-861. doi: 10.1016/j.tjog.2020.08.002. doi: 10.1016/j.tjog.2020.08.002
[24]	Ilhan ZE, Łaniewski P, Thomas N, et al. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling[J]. EBioMedicine, 2019, 44:675-690. doi: 10.1016/j.ebiom.2019.04.028. doi: S2352-3964(19)30267-1 pmid: 31027917
[25]	Li Y, Yu T, Yan H, et al. Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies[J]. Infect Drug Resist, 2020, 13:1213-1220. doi: 10.2147/IDR.S210615. doi: 10.2147/IDR.S210615 pmid: 32431522
[26]	Petrini CG, Bastos LB, Duarte G, et al. Downregulation of IL-2 and IL-23 in Cervical Biopsies of Cervical Intraepithelial Lesions: A Cross-Sectional Study[J]. Acta Cytol, 2020, 64(5):442-451. doi: 10.1159/000508015. doi: 10.1159/000508015 pmid: 32599588
[27]	Park J, Frizzell H, Zhang H, et al. Flt3-L enhances trans-epithelial migration and antigen presentation of dendritic cells adoptively transferred to genital mucosa[J]. J Control Release, 2021, 329:782-793. doi: 10.1016/j.jconrel.2020.10.012. doi: 10.1016/j.jconrel.2020.10.012
[28]	Sun Z, Ge X, Qiu B, et al. Vulvovaginal candidiasis and vaginal microflora interaction: Microflora changes and probiotic therapy[J]. Front Cell Infect Microbiol, 2023, 13:1123026. doi: 10.3389/fcimb.2023.1123026. doi: 10.3389/fcimb.2023.1123026
[29]	France M, Alizadeh M, Brown S, et al. Towards a deeper understanding of the vaginal microbiota[J]. Nat Microbiol, 2022, 7(3):367-378. doi: 10.1038/s41564-022-01083-2. doi: 10.1038/s41564-022-01083-2 pmid: 35246662
[30]	翟青枝, 任腾杰, 付玉荣, 等. 生育晚期各级别宫颈病变患者宫颈微生态的特征[J]. 南方医科大学学报, 2020, 40(12):1768-1775. doi: 10.12122/j.issn.1673-4254.2020.12.11. doi: 10.12122/j.issn.1673-4254.2020.12.11
[31]	Brotman RM, Shardell MD, Gajer P, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection[J]. J Infect Dis, 2014, 210(11):1723-1733. doi: 10.1093/infdis/jiu330. doi: 10.1093/infdis/jiu330 pmid: 24943724
[32]	Martins B, Guimarães RA, Alves R, et al. Bacterial vaginosis and cervical human papillomavirus infection in young and adult women: a systematic review and meta-analysis[J]. Rev Saude Publica, 2023, 56:113. doi: 10.11606/s1518-8787.2022056004412. doi: 10.11606/s1518-8787.2022056004412
[33]	Palma E, Recine N, Domenici L, et al. Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection[J]. BMC Infect Dis, 2018, 18(1):13. doi: 10.1186/s12879-017-2938-z. doi: 10.1186/s12879-017-2938-z pmid: 29304768
[34]	Ou YC, Fu HC, Tseng CW, et al. The influence of probiotics on genital high-risk human papilloma virus clearance and quality of cervical smear: a randomized placebo-controlled trial[J]. BMC Womens Health, 2019, 19(1):103. doi: 10.1186/s12905-019-0798-y. doi: 10.1186/s12905-019-0798-y
[35]	DI Pierro F, Criscuolo AA, Dei Giudici A, et al. Oral administration of Lactobacillus crispatus M247 to papillomavirus-infected women: results of a preliminary, uncontrolled, open trial[J]. Minerva Obstet Gynecol, 2021, 73(5):621-631. doi: 10.23736/S2724-606X.21.04752-7. doi: 10.23736/S2724-606X.21.04752-7
[36]	Hu S, Hao Y, Zhang X, et al. Lacticaseibacillus casei LH23 Suppressed HPV Gene Expression and Inhibited Cervical Cancer Cells[J]. Probiotics Antimicrob Proteins, 2023, 15(3):443-450. doi: 10.1007/s12602-021-09848-7. doi: 10.1007/s12602-021-09848-7
[37]	Das S, Bhattacharjee MJ, Mukherjee AK, et al. Recent advances in understanding of multifaceted changes in the vaginal microenvironment: implications in vaginal health and therapeutics[J]. Crit Rev Microbiol, 2023, 49(2):256-282. doi: 10.1080/1040841X.2022.2049696. doi: 10.1080/1040841X.2022.2049696
[38]	Komatsu A, Igimi S, Kawana K. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells[J]. Vaccine, 2018, 36(24):3423-3426. doi: 10.1016/j.vaccine.2018.05.009. doi: S0264-410X(18)30615-7 pmid: 29735324
[39]	Park YC, Ouh YT, Sung MH, et al. A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3[J]. J Gynecol Oncol, 2019, 30(6):e88. doi: 10.3802/jgo.2019.30.e88. doi: 10.3802/jgo.2019.30.e88